Cargando…

A nomogram incorporating Ki67 to predict survival of acral melanoma

BACKGROUND: The proliferation marker Ki67 is associated with the progression and prognosis of melanoma. However, its prognostic impact on acral melanoma (AM) remains unclear. METHODS: A total of 314 AM patients were enrolled from a cohort of 5758 patients with melanoma at Peking University Cancer Ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Yu, Li, Caili, Mao, Lili, Wei, Xiaoting, Bai, Xue, Chi, Zhihong, Cui, Chuanliang, Sheng, Xinan, Lian, Bin, Tang, Bixia, Wang, Xuan, Yan, Xieqiao, Li, Siming, Zhou, Li, Guo, Jun, Si, Lu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587210/ https://www.ncbi.nlm.nih.gov/pubmed/37470854 http://dx.doi.org/10.1007/s00432-023-05127-w

Ejemplares similares

Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma
por: Tang, Lirui, et al.
Publicado: (2022)

A Functional Synonymous Variant in PDGFRA Is Associated with Better Survival in Acral Melanoma
por: Dai, Jie, et al.
Publicado: (2020)

Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial
por: Mao, Lili, et al.
Publicado: (2021)

The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma
por: Wei, Xiaoting, et al.
Publicado: (2020)

Efficacy Evaluation of Imatinib for the Treatment of Melanoma: Evidence From a Retrospective Study
por: Wei, Xiaoting, et al.
Publicado: (2019)

Risk Models for Advanced Melanoma Patients Under Anti-PD-1 Monotherapy—Ad hoc Analyses of Pooled Data From Two Clinical Trials
por: Bai, Xue, et al.
Publicado: (2021)

Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials
por: Zhou, Li, et al.
Publicado: (2021)

Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis
por: Sheng, Xinan, et al.
Publicado: (2016)

Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies
por: Tian, Hui, et al.
Publicado: (2021)

Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study
por: Zhou, Li, et al.
Publicado: (2022)

The Impact of Liver Metastasis on Anti-PD-1 Monoclonal Antibody Monotherapy in Advanced Melanoma: Analysis of Five Clinical Studies
por: Wang, Xuan, et al.
Publicado: (2020)

Primary malignant melanoma of the esophagus: A retrospective analysis of clinical features, management, and survival of 76 patients
por: Wang, Xuan, et al.
Publicado: (2019)

Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy
por: Dai, Jie, et al.
Publicado: (2023)

Safety and Efficacy of Apatinib Combined with Temozolomide in Advanced Melanoma Patients after Conventional Treatment Failure()
por: Cui, ChuanLiang, et al.
Publicado: (2018)

Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy
por: Wang, Xuan, et al.
Publicado: (2020)

OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study
por: Cui, ChuanLiang, et al.
Publicado: (2022)

Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective study
por: Wei, Xiaoting, et al.
Publicado: (2022)

Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis
por: Li, Siming, et al.
Publicado: (2022)

Systemic Immune-Inflammation Index and Circulating T-Cell Immune Index Predict Outcomes in High-Risk Acral Melanoma Patients Treated with High-Dose Interferon
por: Yu, Jiayi, et al.
Publicado: (2017)

Surgical Outcomes of Vaginal or Cervical Melanoma
por: Tian, Hui, et al.
Publicado: (2022)

Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma
por: Sheng, Xinan, et al.
Publicado: (2020)

Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patients
por: Tang, Bixia, et al.
Publicado: (2019)

TERT copy gain predicts the outcome of high-dose interferon α-2b therapy in acral melanoma
por: Yu, Sifan, et al.
Publicado: (2018)

Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G(4) Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial
por: Sheng, Xinan, et al.
Publicado: (2019)

HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population
por: Zhou, Li, et al.
Publicado: (2023)

Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: A study of 522 consecutive cases
por: Chi, Zhihong, et al.
Publicado: (2011)

High G2 and S‐phase expressed 1 expression promotes acral melanoma progression and correlates with poor clinical prognosis
por: Xu, Tianxiao, et al.
Publicado: (2018)

Increased AURKA Gene Copy Number Correlates with Poor Prognosis and Predicts the Efficacy of High-dose Interferon Therapy in Acral Melanoma
por: Yan, Junya, et al.
Publicado: (2018)

Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions
por: Mao, Lili, et al.
Publicado: (2021)

MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways
por: Ma, Meng, et al.
Publicado: (2019)

MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways: Erratum
por: Ma, Meng, et al.
Publicado: (2022)

Ki67 Antigen as a Predictive Factor for Prognosis of Sinonasal Mucosal Melanoma
por: Kim, Dong-Kyu, et al.
Publicado: (2008)

Nomogram based on MRI for preoperative prediction of Ki-67 expression in patients with intrahepatic mass cholangiocarcinoma
por: Chen, Xiang, et al.
Publicado: (2022)

Advanced acral melanoma
por: Lambert Smith, Franki, et al.
Publicado: (2015)

Nomogram for Predicting Overall Survival in Acral Lentiginous Melanoma: A Population‐based Study
por: Yin, Tingting, et al.
Publicado: (2021)

Deep learning–based radiomic nomograms for predicting Ki67 expression in prostate cancer
por: Deng, Shuitang, et al.
Publicado: (2023)

Prognostic and Clinicopathological Value of Ki-67 in Melanoma: A Meta-Analysis
por: Liu, Qixin, et al.
Publicado: (2021)

Acral Melanocytic Neoplasms: A Comprehensive Review of Acral Nevus and Acral Melanoma in Asian Perspective
por: Park, Sanghyun, et al.
Publicado: (2022)

Spectral CT imaging parameters and Ki-67 labeling index in lung adenocarcinoma
por: Chen, Mailin, et al.
Publicado: (2020)

Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma
por: Li, Siming, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_i2ocrj38hk481adl44poqnf6ls